AzTrials
AzTrials

Hepatocellular CarcinomaPhase 2ABE-LIVERNCT05448677

Ezurpimtrostat Autophagy Inhibitor in Association With Atezolizumab-Bevacizumab in First Line Treatment of Unresectable Hepatocellular Carcinoma

A Phase 2 study testing Ezurpimtrostat, Atezolizumab and Bevacizumab in people with Hepatocellular Carcinoma, run by University Hospital, Grenoble at 1 site in France.

Terminated

Stopped early. The study ended before it was planned to and will not resume.

Official record
Search all trials

Trial summary

The study will assess the efficacy of Ezurpimtrostat in association with standard of care (Atezolizumab-Bevacizumab), compared to standard of care alone, as first line treatment in patients with unresectable hepatocellular carcinoma.The study drug which is tested is the Ezurpimtrostat in association with… Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Hepatocellular Carcinoma
What is being tested?
Ezurpimtrostat, Atezolizumab and Bevacizumab
Could I receive a placebo?
No, everyone receives an active treatment
How many people
3 participants
Where
1 siteFrance
Study dates
15 Dec 2022to 8 Mar 2024
Phase
Phase 2
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Males or females ≥ 18 years of age
  • Histologically confirmed (liver biopsy within 6 previous months) and documented non resectable or metastatic HCC
  • No prior systemic therapy for advanced HCC
  • Liver tumor burden< 50% of the liver (per Investigator judgment)
  • Child-Pugh A (≤ 6) without any history of cirrhotic decompensation within the past 6 months
  • Antiviral therapy required in hepatitis B virus patients (Hepatitis B antigen positive)
Show all 22Show fewer
  • Presence of a measurable tumor per RECIST v1.1 criteria
  • Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1
  • Life expectancy ≥ 12 weeks
  • In case of cirrhosis, last esophageal varices detection by esogastroduodenal endoscopy have to be performed within last the 6 months before inclusion and since macro-vascular invasion diagnosis
  • Adequate hematologic function prior to the first dose of Ezurpimtrostat, defined as:
  • 11.1. Absolute neutrophils count ≥ 1500 cells/µL 11.2. Hemoglobin ≥ 9 g/dL with no transfusion within 4 weeks prior to first planned dose of Ezurpimtrostat 11.3. Platelet count > 50,000/µL with no transfusion within 2 weeks prior to first planned dose of Ezurpimtrostat
  • Adequate renal function prior to first dose, defined as 12.1. Serum creatinine < 1.5 ULN 12.2. Creatinine clearance ≥ 30 mL/min/m2 (by Cockroft-Gault equation of 24-hour urine) if creatinine ≥ 1.5 X ULN
  • Adequate hepatic function prior to first dose, defined as AST/ALT ≤ 5 X ULN
  • Women patients of childbearing potential* must have a negative blood pregnancy test at screening and baseline, and be willing to use a highly effective** contraception. The patient should be advised to continue the contraception for at least 6 months following the completion of dosing. Women with cessation for > 24 months of previously occurring menses, or women of any age who have had a hysterectomy, or have had both ovaries removed will be considered to be of non-childbearing potential
  • Male patients of reproductive potential must be willing to use one acceptable method of contraception, as judged by Investigator and Sponsor, and to refrain from donating sperm from the time of screening through at least 6 months following the completion of dose administration
  • Amenable to computed tomography (CT) with 3 or 4 phase liver or magnetic resonance imaging (MRI) of abdomen and pelvis, and CT of chest, or MRI of whole body, for initial tumor size measurements and subsequent follow-up
  • Absence of other clinically relevant abnormalities (i.e., those which do not require medical intervention) for screening laboratory test results as judged by the Investigator and Sponsor
  • Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures
  • Able to understand and provide written informed consent
  • Patients covered by Health Insurance System
  • According to CTFG guideline, a woman is considered of childbearing potential (WOCBP), i.e. fertile, following menarche and until becoming post-menopausal unless permanently sterile. Permanent sterilization methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy ** Highly effective birth control method include (according to CTFG guideline): combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal, transdermal); progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable); intrauterine device; intrauterine hormone-releasing system; bilateral tubal occlusion; vasectomized partner; sexual abstinence.

Who cannot join

  • Any known history of encephalopathy
  • Untreated or incompletely treated esophageal and/or gastric varices with bleeding or high-risk for bleeding
  • Known esophageal varices with recent history of bleeding (within previous 6 months)
  • Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures
  • Known fibrolamellar HCC, sarcomatoid HCC, or mixed cholangiocarcinoma and HCC
  • Chronic treatment with immunosuppressive agents (like steroids) ≤ 6 weeks prior to first planned dose of treatment
Show all 38Show fewer
  • Major surgical procedures, open biopsy or significant traumatic injury ≤ 4 weeks prior to first dose of treatment or anticipation of major surgical procedure during the course of the trial, minor surgical procedures ≤ 1 week of first planned dose
  • Local therapy to liver within 28 days prior to initiation of study treatment or non-recovery from side effects of any such procedure
  • Any clinically significant cardiovascular condition as judged by the Investigator (such as New York Heart Association Class II or greater cardiac failure, myocardial infarction, or cerebrovascular accident within 3 months prior to Day 1 of Cycle 1, inadequately controlled arterial hypertension, unstable arrhythmia, or unstable angina)
  • Severe or uncontrolled renal condition
  • Untreated chronic hepatitis B
  • HCV infection
  • Known history of immunodeficiency diseases (e.g., active HIV)
  • Use of any prohibited concomitant medications within 14 days of the Baseline/Day 1 visit
  • Contraindication to additional liver biopsy planned between C4 and C5
  • Contraindication to iodinated contrast agent infusion or gadolinium chelate-based contrast infusion
  • Known current alcohol (> 20g/ Day in women and > 30g/ Day in men) or substance abuse
  • Malabsorption issues (e.g., gastric bypass or gastrectomy patients)
  • History of leptomeningeal disease
  • Active or history of autoimmune disease
  • History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography scan
  • Known active tuberculosis
  • History of malignancy other than HCC within 3 years prior to screening, with the exception of adequately treated skin basal cell carcinoma, squamous cell carcinoma or other non-melanomatous skin cancer, in-situ carcinoma of the uterine cervix, or prostate cancer that is controlled by hormone therapy (patients may continue hormone therapy while on study)
  • Pregnancy or breastfeeding, or intention of becoming pregnant during study treatment or within at least 6 months after the last dose of treatment
  • Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases
  • Uncontrolled tumor-related pain
  • Uncontrolled or symptomatic hypercalcemia
  • Treatment with systemic immunostimulatory agents
  • Prior history of hypertensive crisis or hypertensive encephalopathy
  • Evidence of bleeding diathesis or significant coagulopathy
  • History of intestinal obstruction and/or clinical signs or symptoms of GI obstruction including sub-occlusive disease related to the underlying disease or requirement for routine parenteral hydration
  • Serious, non-healing or dehiscing wound, active ulcer, or untreated bone fracture
  • Metastatic disease that involves major airways or blood vessels, or centrally located mediastinal tumor masses
  • Known clinically significant or life threatening organ or systemic disease such that in the opinion of the Investigator, the significance of the disease will compromise the patient's participation in the trial
  • Known intolerance or hypersensitivity to the active ingredient or to one of the components of the study drug
  • Subject in exclusion period for another study
  • Subject who cannot be contacted in an emergency
  • All persons protected: pregnant or parturient women, breastfeeding mothers, persons deprived of liberty by judicial or administrative decision, persons subject to a legal protection measure

Trial locations and contacts

1 site in 1 country.

France1 site

  • University Hospital

    Grenoble, 38043

Other trials in France

About this study

Official title: Ezurpimtrostat Autophagy Inhibitor in Association With Atezolizumab-Bevacizumab in First Line Treatment of Unresectable Hepatocellular Carcinoma, a Phase 2b Randomized Trial

The study will assess the efficacy of Ezurpimtrostat in association with standard of care (Atezolizumab-Bevacizumab), compared to standard of care alone, as first line treatment in patients with unresectable hepatocellular carcinoma.The study drug which is tested is the Ezurpimtrostat in association with Atezolizumab-Bevacizumab to allow a better tumor response as well as better survival outcomes with an acceptable safety.

Read the detailed description

The study is a multicentric, prospective, comparative, randomized, open-label phase 2b trial. This study will enroll 187 to 196 patients and consists of 2 parts: Safety Lead-in Phase and Expansion Phase. Initially, 3 to 12 patients will be enrolled into a Safety Lead-in Phase based on a 3 + 3 design, with the possibility of dose de-escalation, to confirm the recommended dose of Ezurpimtrostat.The randomized Expansion Phase will start after completion of Safety Lead-in Phase at the confirmed dose and will include 184 patients. Patients will be randomly assigned between experimental arm (Ezurpimtrostat + Atezolizumab-Bevacizumab) and control arm (Atezolizumab-Bevacizumab) according to a 1:1 repartition.

Being tested
Ezurpimtrostat, Atezolizumab, Bevacizumab
Medical subject headings
Carcinoma, Hepatocellular

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • EzurpimtrostatDrug

    Patients in the experimental arm will be instructed to take their assigned oral dose every day.

  • AtezolizumabDrug

    Atezolizumab will be administered by IV infusion at a fixed dose of 1200 mg on Day 1 of each 21-days cycle

  • BevacizumabDrug

    Bevacizumab will be administered by IV infusion at a dose of 15 mg/kg on Day 1 of each 21-day cycle.

Study groups in NCT05448677
Study groupRoleWhat they receive
ExperimentalExperimentalEzurpimtrostat+Atezolizumab-Bevacizumab
Receives: Drug: Ezurpimtrostat; Drug: Atezolizumab; Drug: Bevacizumab
ControlActive comparatorAtezolizumab-Bevacizumab
Receives: Drug: Atezolizumab; Drug: Bevacizumab

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Progression-Free Survival (PFS)

    Progression-Free Survival (PFS), defined as the time from randomization to the occurrence of disease progression or death from any cause, whichever occurs first.

    Progression events will be considered based on centralized tumor response assessment according to RECIST version 1.1 and PFS analyses will be performed by the CHU Grenoble Alpes Statistics department.

    Measured: At 36 months

Secondary outcomes (1)

  1. Objective response rate (ORR)

    Best overall objective response rate (ORR) and ORR at 3,6,9,12 months according to RECIST 1.1 and IRF-assessed tumor response according to HCC mRECIST

    Measured: At 3,6,9,12 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted7 Jul 2022
  2. Study start15 Dec 2022
  3. Primary completion8 Mar 2024
  4. Study completion8 Mar 2024

Why it stopped: Study terminated due to recruitement issues

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
3 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05448677
Sponsor's protocol ID
38RC21.0434
Acronym
ABE-LIVER
Status last verified
Apr 2025
First submitted
27 Jun 2022
Last updated
20 Apr 2025
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing Ezurpimtrostat, Atezolizumab and Bevacizumab in people with Hepatocellular Carcinoma, run by University Hospital, Grenoble at 1 site in France.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 22 inclusion and 38 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: stopped early, as of the sponsor's last update on 20 Apr 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study was stopped early (reason given: Study terminated due to recruitement issues). Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Progression-Free Survival (PFS) (time frame: At 36 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05448677.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Apr 2025.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in